Combining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
Meibomian Gland Dysfunction, developing the first Pharmaceutical for the Treatment of Meibomian Gland Dysfunction
Certa Therapeutics novel drugs block a receptor that is a key driver of fibrosis (scarring) of the kidney and other organs. Certa is able to use genetic analysis to identify those patients that are most likely to benefit from therapy.
A first in class orally available medicine for the treatment of fibrotic and inflammatory indications associated with type 2 diabetes and metabolic syndrome with an initial focus on liver fibrosis (NASH – non-alcoholic steatohepatitis).
Developing vaccines that target the major virulence factors produced by the bacterium Porphyromonas gingivalis (P gingivalis)
EBR Systems is a clinical stage company that is developing therapies for patients with cardiac rhythm diseases and heart failure using wireless cardiac stimulation.
Ena Respiratory is a biotechnology company aiming to transform the treatment and prevention of respiratory infections. The company initial focus is to target respiratory infections in patients with asthma and COPD.